deltatrials
Completed PHASE2 NCT02918006

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

Phase 2 Randomized, Controlled, Human Influenza A (H1N1) Challenge Study Following Administration of an Oral H1N1 HA Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant to Healthy Adult Volunteers

Sponsor: Biomedical Advanced Research and Development Authority

Conditions Influenza
Interventions Fluzone® Placebo Tablets Saline Solution for Placebo IM Injection VXA-A1.1
Updated 9 times since 2017 Last updated: Oct 2, 2022 Started: Aug 31, 2016 Primary completion: Aug 8, 2017 Completion: Jan 19, 2018

Listed as NCT02918006, this PHASE2 trial focuses on Influenza and remains completed. Sponsored by Biomedical Advanced Research and Development Authority, it has been updated 9 times since 2016, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Sep 2022 — Nov 2022 [monthly]

    Completed PHASE2

  5. Apr 2022 — Sep 2022 [monthly]

    Completed PHASE2

▶ Show 4 earlier versions

  1. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

  2. Aug 2018 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  3. Feb 2017 — Aug 2018 [monthly]

    Recruiting PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Aug 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Biomedical Advanced Research and Development Authority
  • Vaxart
Data source: Vaxart

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Costa Mesa, United States